Kornimate/medical-research-clean huggingface dataset:
brief intervention for chronic pain and history of stressful experiences

Conditions: Chronic Pain; Trauma; Adverse Childhood Experiences

Summary: the goal of this study is to understand whether a brief, three session program can be helpful in reducing symptoms related to both chronic pain and stressful experiences/trauma.


Eligibility criteria:
inclusion criteria: * presence of a chronic pain condition (pain for at least 3 months or more) * history of psychosocial trauma or stressful experience (adverse childhood events questionnaire \[aces\] score of ≥ 3 or trauma history questionnaire score \[thq\] of ≥ 2) * english fluency * access to a smartphone, laptop, or computer * able to participate in the intervention via a virtual platform exclusion criteria: * unable to participate in 3 weekly sessions * unable to complete study procedures due to the presence of delirium, dementia, psychosis, or other cognitive impairment
study to evaluate the efficacy and safety of k-877-er and csg452 in participants with nash with liver fibrosis

Conditions: NASH

Summary: a study to investigate the use of combination therapy with two investigational products for the treatment of adult patients with nonalcoholic steatohepatitis (nash).


Eligibility criteria:
inclusion criteria: * able to understand and comply with study procedures and give written informed consent * age ≥18 years * nas ≥4 with a score of at least 1 in each component of the nas (steatosis, lobular inflammation, and ballooning) at visit 2 liver biopsy, or a historical liver biopsy performed within 24 weeks of randomization * fibrosis stage of 1 or greater and below 4 on nash crn (clinical research network) fibrosis staging system at visit 2 liver biopsy, or a historical liver biopsy performed within 24 weeks of randomization * meet all inclusion criteria outlined in clinical study protocol exclusion criteria: * participation in another clinical trial involving an investigational agent within 30 days prior to signing the informed consent form (icf) for this study * ongoing or recent consumption of greater than moderate amounts of alcohol as defined in clinical study protocol * evidence of other forms of chronic liver disease as defined in clinical study protocol * does not meet any other exclusion criteria outlined in clinical study protocol
proteomics in multiple trauma to identify organ failure

Conditions: Multiple Trauma

Summary: to analyse differences in protein expression in multiple trauma patients for identification of potential biomarkers to predict organ dysfunction.

the aim of the present study in humans is to analyse differences in protein expression after multiple trauma in patients for identification of potential biomarkers to predict organ dysfunction.

Eligibility criteria:
inclusion criteria: * older than 18 years * multiple trauma patients * iss \>16 exclusion criteria: * children * iss \<16

Keywords: proteomics multiple trauma organ dysfunction
olanzapine for the prevention of postoperative nausea and vomiting

Conditions: Postoperative Nausea

Summary: nausea and vomiting (ponv) remain a common problem in surgical units. even after two or three prophylactic antiemetic interventions, patients with all four of the apfel risk factors for ponv have an estimated 30 to 40% chance of suffering ponv. olanzapine as an antiemetic represents a new use of an antipsychotic drug.

aim of the research, to compare the effects of oral 10 and 5 mg olanzapine for the prevention of postoperative nausea and vomiting

Eligibility criteria:
inclusion criteria: * asa i and ii patients * undergoing ambulatory laparoscopic gynecologic surgery with general anesthesia * patients have at least two of the four apfel risk factors for ponv2 * lack of history of psychiatric and psychotic illnesses. exclusion criteria: * asa iii and ≥ iv patients * psychological diseases * history of chemotherapy * have a pre-existing vestibular disorder or history of dizziness or preexisting nausea or vomiting in the 24 h before surgery, or were being treated with regular antiemetic therapy including systemic corticosteroids.
relevance of veinous lactates to predict postoperative complications in children 0-1 years

Conditions: General Anesthesia; Infant

Summary: this study will investigate if the dosage of veinous lactate at the end of a surgical procedure is related to post-operative complications occurring within 3 months in young infants aged 0-1 years. blood samples are acquired routinely before emergence of general anesthesia, from the iv line put in place for anesthesia. the investigators hypothesized that elevated lactates would be associated with more postoperative complications in this population, as is the case in adults.


Eligibility criteria:
inclusion criteria: * surgery under general anesthesia * age \< 1 year exclusion criteria: * ambulatory surgery * cardiac surgery * preoperative hemodynamic instability * weight \< 2 kg

Keywords: pediatric anesthesia lactate complications
the study assessing the safety and efficacy of ok-101 treatment in subjects with neuropathic corneal pain

Conditions: Neuropathic Pain

Summary: the primary objective of this study, in subjects with neuropathic corneal pain, is to evaluate the efficacy and safety of ok-101 0.05% and 0.1% as compared to placebo instilled 4 times/day in subjects with neuropathic corneal pain, as assessed by visual analogue scale (vas).

detailed description: neuropathic corneal pain (ncp) is a complex disease affecting the somatosensory nervous system characterized by different underlying etiologies and pathogenesis. ok-101 is a lipid conjugated chemerin peptide antagonist of the chemr23 g-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response. ok-101 has been shown to produce anti-inflammatory and pain-reducing activities in mouse models of dry eye disease and neuropathic corneal pain; and is designed to combat washout through the inclusion of the lipid 'anchor' contained in the candidate drug molecule to enhance the residence time of ok-101 within the ocular environment. our preclinical studies have shown that treatment with ok-101 abolishes corneal pain in a murine model of ncp.

Eligibility criteria:
inclusion criteria: 1. male or female aged ≥ 18 years. 2. symptoms of neuropathic corneal pain for at least 3 months, such as burning, stinging, light sensitivity, discomfort, or pain. 3. positive ivcm findings evaluated by an experienced ophthalmologist (pedram hamrah, m.d.): decreased nerve density and evidence of microneuromas. 4. females of childbearing potential must have a negative pregnancy test. 5. best corrected distance visual acuity (bcdva), using corrective lenses, if necessary, in the study eye of at least +1.0 log mar (snellen \<20/200). 6. satisfying all informed consent requirements. 7. ability and willingness to comply with study procedures. exclusion criteria: 1. evidence of any active ocular infection. 2. evidence of any intraocular inflammation. 3. evidence of any persistent epithelial defect/ulcer. 4. evidence of any corneal scar/corneal edema. 5. presence of any other ocular conditions that require topical medications during the treatment phase. 6. history of severe systemic allergy or severe ocular allergy. 7. inability to suspend topical medications 8 days prior to the starting date. 8. inability to continue oral medications for ncp without changes during the study duration. 9. no changes or less than 50% improvement in vas score after topical 0.5% proparacaine hydrochloride (alcaine, alcon, fort worth, tx). 10. history of any ocular surgery within three months before study visit 1(day 0). 11. ocular surgery expected during the 16 weeks of the trial. 12. use of refractive/therapeutic contact lenses during the study period. 13. female subjects who are pregnant/have a positive pregnancy test result or are breastfeeding or intend to become pregnant during the study treatment period. 14. drug addiction/alcohol abuse within the last year. 15. participation in another clinical trial concurrently.
feasibility study of deep brain recordings for learning and memory

Conditions: Movement Disorders

Summary: background: - some people with movement disorders are in another nih protocol. they will have electrodes placed in deep brain areas. they may do tasks before, during, and after surgery. researchers want to learn more about how brain cells and networks work while people learn and remember. they want to use the data from the other nih study to do this. objective: - to share data from before and during deep brain stimulation surgery. the data will be used in a study of how the brain learns and remembers. eligibility: - people at least 18 years old who are in protocol 11-n-0211 and have certain movement disorders. design: * as part of protocol 11-n-0211, data on participants brainwave activity is collected. in this protocol, they will have that data stored and shared. * researchers will access imaging data from deep brain stimulation surgery. * researchers will access other medical records.

objectives: the purpose of this protocol is to share neural data collected before and during deep brain stimulation surgery with the university of pennsylvania to identify biomarkers of successful learning and memory. study population: up to twenty (20) adult subjects who are participating in nih protocol 11-n-0211 deep brain stimulation surgery for movement disorders who provide written informed consent for sharing and the additional use of their data. study design: this protocol only involves providing consent to share learning and memory data collected under protocol 11-n-0211. there are no separate or additional participant procedures involved in this protocol.

Eligibility criteria:
* inclusion criteria: adults at least age 18 currently enrolled in 11-n-0211 exclusion criteria: unable to provide own informed consent

Keywords: memory testing biomarkers learning
cellular immunotherapy for relapsed or refractory lymphoma data collection

Conditions: Lymphoma, Non-Hodgkin

Summary: this study aims to collect clinical data from adult patients with relapsed or refractory non-hodgkin's lymphoma (r/r nhl) receiving cellular immunotherapy to establish a large database of cellular immunotherapy for chinese patients.

this study aims to collect efficacy and safety data from adult patients with r/r nhl who received cellular immunotherapy between january 2017 and december 2040. study investigators will determine the most appropriate diagnostic and treatment plans for patients based on clinical practice, without any intervention due to the existence of this study. no grouping will be conducted, and subgroup analyses will be performed based on the collected data. data collection process: clinical data will be collected from patients before cellular immunotherapy, before immune cell infusion, on the day of infusion, and at the last visit or follow-up within 24 months post-infusion. this includes collecting efficacy data, adverse events related to cellular immunotherapy, and survival data. additionally, any new tumors, pathological findings, and other relevant laboratory or auxiliary examination data will be collected.

Eligibility criteria:
inclusion criteria: * adult patients with a confirmed diagnosis of r/r b-nhl (including r/r dlbcl, r/r fl, r/r mcl, hgbl-nos, fl3b, r/r mzl, transformed lymphomas such as mcl) and r/r t-cell lymphoma, who have received informed consent waivers; * patients who have received or are receiving cellular immunotherapy, with cellular immunotherapy products including the following categories: cytokine-induced killer cell therapy (cik), tumor-infiltrating lymphocytes (til), cytokine-induced killer cell-dendritic cell mixed therapy (dc-cik), chimeric antigen receptor t cells, nk cells or macrophage therapy (car-t, car-nk, car-m), t-cell receptor chimeric t cell therapy (tcr-t), dendritic cell therapy. exclusion criteria: * na

Keywords: car-t
sympathetic regulation of large artery stiffness in humans with ish

Conditions: Hypertension, Systolic; Stiffness, Aortic

Summary: stiffening of your blood vessels, particularly the large vessels from your heart (called the aorta and carotids) you age contributes to the development of cardiovascular disease (cvd) such as heart attack and stroke. nerve activity from your brain to your body also increases with advancing age but it is unknown if this nerve activity contributes directly to the stiffening on your blood vessels in older adults in addition to high blood pressure. therefore, successful completion of the proposed aims will have a significant clinical impact by identifying if nerve activity from your brain could be a novel target for therapies that would lower stiffness of the aorta and carotid arteries in older adults.


Eligibility criteria:
inclusion criteria: * age 60-85 * non-smoking * clinically healthy * untreated or treated stage 1 isolated systolic hypertension (ish) (systolic bp 130-139 mmhg; diastolic bp \<90 mmhg) or stage 2 ish (systolic bp 140-159 mmhg; diastolic bp \<90 mmhg) per 2017 aha/acc hypertension guidelines * if subject is on antihypertensive medications, they will stop taking medication for a one-week washout period after visit 1 before they return for visit 2. they will come in at day 3 and day 7 of the one-week washout for a bp reading, to confirm that systolic bp is \<160 mmhg. exclusion criteria: * no history of cardiovascular disease (e.g., myocardial infarction, bypass surgery, angioplasty/stent, heart failure, cardiomyopathy, pacemaker/defibrillator, peripheral artery disease), pulmonary disease, liver disease, type i or ii diabetes, cancer (treated by chemotherapy and/or radiation), psychiatric illness, on aspirin or other non-steroidal anti-inflammatory drugs (nsaids). * aspirin, nsaids, vitamins, herbal supplements, omega-3-fatty acids will have to discontinue for at least 1 week before participation and remain discontinued during the study. * blood thinners, serotonin reuptake inhibitors (ssris), or pde5 inhibitors will also be excluded. * women must be postmenopausal for at least 6 months (surgical or natural) and not currently on hormone replacement therapy. * subjects not on antihypertensive will not be eligible if their resting clinic systolic bp is \ 160 mmhg and diastolic bp \>90 mmhg.
effect of initial empirical peep setting on the esophageal pressure-guided peep titration in ards

Conditions: ARDS, Human; PEEP, Occult; Esophageal and Pleural Pressure

Summary: esophageal manometry was used as surrogate of pleural pressure to titrate positive end-expiratory pressure (peep) in ards patients. however, absolute values of esophageal pressure (pes) could be affected by the peep setting. in moderate to severe ards patients, the end-expiratory pes changed differently with peep adjustment. and the esophageal phenotypes could be divided into type i and type ii. with type i （δpes≥30%δpeep）and type ii（δpes\<30%δpeep）.


Eligibility criteria:
inclusion criteria: - aged over 18 all the moderate to severe ards patients invasive mechanical ventilation exclusion criteria: * aged\<18 contraindication to esophageal catheter
biomarker study of elotuzumab in high risk smoldering myeloma

Conditions: Smoldering Multiple Myeloma

Summary: the purpose of this study is to determine whether elotuzumab will improve response in patients with high risk smoldering myeloma who have more cd56\^dim cells (a marker for the health of the body's immune system)

intervention model: dosing is sequential

Eligibility criteria:
for more information regarding bms clinical trial participation, please visit www.bmsstudyconnect.com. key inclusion criteria: participants with a confirmed diagnosis, according to criteria of the international myeloma working group, of smoldering multiple myeloma, considered high risk according to the following: * serum monoclonal (m) protein ≥3 gm/dl and bone marrow plasma cells (bmpc) ≥10% or * serum m protein 1-3 g/dl and bmpc ≥10% and abnormal free light chain ratio of \ 8.0 * urine m protein \>200 mg/24 hours, ≥10% bmpc, and serum free light chain ratio ≤0.125 or ≥8.0 key exclusion criteria: * active multiple myeloma * monoclonal gammopathy of undetermined significance * active plasma cell leukemia * positive for hepatitis b or c virus or hiv infection
effect of ppv+ilm peeling +/- subretinal injection of ringer lactate in management of nontractional refractory dme

Conditions: Efficacy; Safety

Summary: to evaluate the efficacy and safety of combined pars plana vitrectomy and planned foveal detachment through subretinal injection of ringer's solution in patients with non-tractional refractory diabetic macular edema.

in non-tractional cases, ppv allows a more efficient clearance of vegf and other cytokines from the retina and improves retinal oxygenation by promotion of intraocular fluid currents, and relief of any subclinical tractional forces, thereby reducing dme. to evaluate the efficacy and safety of combined pars plana vitrectomy and planned foveal detachment through subretinal injection of ringer's solution in patients with non-tractional refractory diabetic macular edema.

Eligibility criteria:
inclusion criteria: * age: above 40 years old. * patients with type two diabetes mellitus of more than 5 years duration. * patients with best corrected visual acuity better than 3/60. * central macular thickness (cmt) of more than 250 μm despite undergoing six monthly injection of anti-vegf therapy or corticosteroid or less than 10% reduction in cmt at the last follow up visit. * no evidence of vitreomacular traction. * lens status: pseudophakia or clear crystalline lens. exclusion criteria: other causes of macular edema (intraocular inflammation, retinal vein occlusion, irvin-gass syndrome, pharmacological). * ischemic maculopathy by ffa. * presence of bad prognostic signs in oct such as disorganization of inner retinal layers (dril) and extensive disruption of is-os junction subfoveally. * presence of apparent retinal pigment epithelium (rpe) atrophy at or near the macula. * presence of proliferative diabetic fibrovascular membranes threatening or at the macula. * presence of diabetic optic atrophy or neuropathy. * presence of neovascular glaucoma. * cataractous lens either preoperatively or as intra or postoperative complication. * vitrectomized eyes. * a prior intraocular surgery within the past six-months. * lost follow up

Keywords: refractory diabetic macular edema internal limiting membrane peeling pars plana vitrectomy subretinal injection of ringer lactate
nerve stimulator versus ultrasound-guided interscalene block for shoulder surgery

Conditions: Pain

Summary: the investigators compared the postoperative analgesia of nerve stimulator-guided and ultrasound-guided interscalene block after shoulder surgery.

ultrasound (us)-guided peripheral nerve block has increased in popularity. it has many advantages such as improved success rate, faster onset time, fewer needle passes, shorter performance time, and reduced procedural pain and vascular puncture. however, there is no information about postoperative analgesia. therefore, the investigators tested whether nerve stimulator (ns) - guided interscalene block was inferior to ultrasound-guided block in terms of duration of postoperative analgesia for shoulder surgery.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologists physical class i - iii patients scheduled to undergo shoulder surgery exclusion criteria: * coagulopathy, severe pulmonary disease, neuropathy, contralateral diaphragmatic paresis, allergy to study medications

Keywords: ultrasound nerve stimulator
impact of onco-sexology support on the quality of life of patients newly diagnosed for cancer

Conditions: Cancer

Summary: onco-sexology as a supportive care for patients treated for cancer is still rarely discussed or even non-existent in 2022. however, it's recommended to integrate the preservation of sexual health throughout the treatment and post-cancer process, given the impact of cancer, treatments and the importance of intimate life for a majority of patients. onco-sexology is one of the supportive care services validated by the french national cancer institute (inca). it is also an objective of the 2014-2019 cancer plan and the 2017-2030 national sexual health strategy plan. although sexuality is one of the fundamental needs of the human being, including in the case of a chronic disease or cancer diagnosis, the lack of training of health professionals to deal with intimate life, the difficulty to exchange on this subject between caregivers and patients, the lack of financial support for onco-sexology consultations, are all obstacles to the global management of oncology patients. however, it's a request from patients to be able to discuss the subject in an intimate way with a professional. while onco-sexology is already recommended as supportive care, a study on the impact of the delay in the management of sexual difficulties on quality of life could provide a sufficient level of evidence to change the practices and the care pathway of the oncology patient. our objective is to study whether early management in onco-sexology has an impact on quality of life compared to late management (ie onco-sexology consultation before vs. after introduction of systemic oncological treatment).


Eligibility criteria:
inclusion criteria: * aged ≥ 18 years * newly cancer diagnosis, including palliative care * having given free and informed written consent exclusion criteria: * pregnant or breastfeeding woman * persons deprived of their liberty by a judicial or administrative decision. * persons who are subject to a legal protection measure or who are unable to express their consent.
the role of functional magnetic resonance imaging in preoperative assessment of primary penile carcinoma

Conditions: Penile Cancer

Summary: the proposed project is intended as a prospective study that includes 60 patients with newly diagnosed penile squamous cell carcinoma (scc) referred to oslo university hospital (ouh), radiumhospitalet, for surgery, primarily organ-sparing surgery (oss). oss may improve not only quality of life, but also quality of sexual function. however, there is a potential for increased risk of local recurrence after oss compared to the amputation of the penis. appropriate preoperative staging, including multi-parametric magnetic resonance imaging (mpmri), can substantially improve selection of patients and decrease the recurrence rate after surgery. mpmri without artificial erection is promising diagnostic tool that is poised to be all-in-one solution for staging and preoperative assessment of primary penile cancer, especially prior to oss. the method is non-invasive and thus comfortable to perform for most of the patients. novel mri techniques are not incorporated into current clinical recommendations, and the potential of new, functional sequences has not been evaluated before. the accuracy of functional, non-erectile mpmri for detecting and staging of primary penile cancer is not known. thus, the main purpose of this study is to assess the diagnostic value of this method for preoperative assessment of penile cancer.


Eligibility criteria:
inclusion criteria: * newly diagnosed penile squamous cell carcinoma (scc) * the patient will benefit from organ-sparing surgery (oss) * signed broad consent for cancer research exclusion criteria: * n/a